Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Climb Bio Inc

CLYM ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$11.01

▲ +7.00%

Market Cap $646.71M · Vol 504.11K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$646.71M

Small Cap

Div Yield

N/A

EPS Growth

+13.09%

YoY

RSI (14)

51.44

Momentum

Beta

0.00

vs Market

52W High

$18.33

39.93% below

52W Low

$1.64

573.39% above

Volume

504.11K

Avg 378.67K

P/B

1.19

Price-to-book

ROE

N/A

Return on equity

Free Float

99.72%

Public shares

Shariah Compliance8 STANDARDS

✗ Climb Bio Inc (CLYM) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CLYM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.04%

+0.09%

-21.36%

-3.17%

YTD

+175.25%

+501.64%

+323.46%

-35.08%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-59,851,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-31.10% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.19
P/FCF	N/A
EPS Growth	+13.09%
Outstanding Shares	58.74M

Technical Indicators

50-Day SMA	$11.84
200-Day SMA	$10.54
RSI (14)	51.44
Beta	0.00
52-Week High	$18.33
52-Week Low	$1.64

Volume Today	504.11K
Avg Daily Volume (30D)	378.67K
Relative Volume	1.33x
Volatility (10D)	99.01
Volatility (30D)	90.81
Free Float	99.72%

Analyst Consensus

STRONG BUY

Current Price $11.01

Mean Target $28.00

52W Low$1.64 52W High$18.33

Current

Target

$1.64 $18.33

Current Analyst target

+154.31% upside potential · 16 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00ZNKL0L5

ISINUS28658R1068

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.27% ARGX.BR argenx SE +4.66% ARGX argenx SE +3.78% GMAB.CO Genmab A/S +3.80% GMAB Genmab A/S +4.05%

Company Profile

Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.